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creativecommons.org/licenses/by-nc-nd/Abstract Vaccines against human papillomavirus (HPV) are available in Europe since 2006.
They have been highly effective in preventing infection and disease caused by the vaccine
types. Clinical efficacy data are available for cervical, vulvovaginal and anal precancer and
invasive cervical cancer. Disease reduction is best with early vaccination and a coverage of
more than 70%. Gender-neutral vaccination provides direct protection for all men and im-
proves the coverage. A good coverage is followed by herd protection of the unvaccinated
men and women. School-based programs appear to be most effective; under the age of 15
years, two doses with an interval of 6e12 months are sufficient. From the age of 15 years,
the standard regimen with three doses is recommended. A broad catch-up program for youngof Surgery & Cancer, Hammersmith Campus, Imperial College, 3rd Floor, Du Cane Road, W12 0NN,
l.ac.uk (M. Kyrgiou).
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
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adult women and men improves the effectiveness. The vaccines are also effective in sexually
active women and men with previous but cleared infections. Vaccination in addition to local
treatment of HPV-related disease appears to reduce recurrent or subsequent HPV-related dis-
ease. Combination of HPV vaccination and screening with HPV testing is the most effective
approach to prevention of cervical cancer. The screening intervals may increase in the vacci-
nated cohorts. The upper age limit for vaccination remains to be evaluated, is country specific
and depends on cost-effectiveness. The European Society of Gynaecologic Oncology and the
European Federation for Colposcopy strongly support gender-neutral vaccination programs
for children and young adolescents, with a catch-up program for young adults.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Since the licensure of the first-generation human papil-
lomavirus (HPV) vaccines in 2006, primary prevention
of the majority of cervical cancer cases is possible.
Meanwhile, we are aware that a substantial fraction of
vulvar and vaginal cancers, most anal cancers and
possibly other neoplasms affecting women and men such
as oral cancers can be prevented. The first generation of
HPV vaccines included the quadrivalent HPV 6/11/16/18
vaccine (Gardasil, MSD) and the bivalent HPV 16/18
vaccine (Cervarix, GSK). From 2015, the second-gen-
eration vaccine, the ninevalent HPV 6/11/16/18/31/33/45/
52/58 vaccine (Gardasil 9, MSD) was licensed in
Europe [1].
More than 50,000 new cases of HPV-related cancers
including 35,000 cervical cancers and 10,000 vulvar and
vaginal cancers are caused by HPV in Europe. In
Europe, HPV 16 causes 66% of invasive cervical cancer
and more than 70% of other HPV-related cancers, fol-
lowed by HPV 18 and 33 [2]. With the second-
generation vaccines, almost 90% of these cases are
potentially preventable. In addition, there is an estimate
of 280,000e540,000 precancerous genital lesions; more
than 80% of these are preventable with the HPV vac-
cines [3e5].2. Trial results
For all three available vaccines, extensive phase III trials
have been performed, including more than 70.000 study
participants across all trials. All three vaccines demon-
strated a robust clinical efficacy that exceeded 95%
against disease related to the vaccine types in subjects
not infected with the analysed vaccine type at the time of
vaccination [1]. This has been demonstrated for the
cervical and vulvovaginal disease in phase III efficacy
studies conducted in young women aged 15 to 26 years.
In a substudy of young men aged 16 to 26 years, the
observed efficacy against anal disease was 75% for the
vaccine types [6]. The clinical efficacy was demonstratedalso in women aged from 15 to 45 years [7]; immuno-
genicity was evaluated in girls and boys from the age of
9 years and for adult women up to the age of 55 years
[8]. Based on these data, all three vaccines are licensed
by European Medicines Agency (EMA) for girls and
boys from the age of 9 years without any upper age
limit.
3. Real-world experience
From the first-generation HPV vaccines, extensive data
on the population-based effect are available for various
countries. Some of the countries with good coverage are
Australia and, in Europe, Denmark, Portugal and the
United Kingdom (UK), whereas coverage remains un-
acceptably low in some European countries and low-
resource settings [9]. Within only three years after the
implementation of the vaccination program with the
quadrivalent vaccine, Australian data reported a
reduction in cervical high-grade squamous intra-
epithelial lesions (HSILs) by half in young women [10],
whereas in Denmark, a reduction of up to 81% was
observed in young women with the same vaccine [11].
Vaccination with the bivalent vaccine in the UK reduced
HPV 16/18 prevalence by 82%, and for non-vaccine
types, HPV 31/33/45 prevalence was reduced by 49%
[12]. Cervical HSIL was reduced by 88% [13] in Scotland
with the bivalent vaccine;the HPV 16/18 prevalence was
reduced by 89%, and for non-vaccine types, HPV 31/33/
45 prevalence was reduced by 85% in those girls vacci-
nated at the age of 12e13 years [14]. The data on the
reduction of infection and disease caused by the HPV
vaccine types are robust and consistent, although the
effect on non-vaccine types appears to be less durable
and data far less consistent [15]. The prevention of
preinvasive lesions has additional benefits as it mini-
mises the reproductive morbidity caused by local treat-
ment for HSIL [16,17]. A combined analysis of clinical
studies in Finland in a total of 190,000 follow-up years is
reported on the impact of vaccination on invasive cancer
[18]. Data reported diagnosis of 10 HPV-related cancers,
including eight cases of invasive cervical cancer, all
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in those being HPV vaccinated during one of these tri-
als. In the US (quadrivalent vaccine), a significant
decrease in the incidence of cervical cancer among
young women after the introduction of HPV vaccine
was observed [19]. Australia projected that cervical
cancer may be eliminated as a public health problem
within the next 20 years [20].
The side-effects of the licensed HPV vaccines are
comparable with those of others. These include pre-
dominantly local reactions, which depend on the quan-
tity of antigen and adjuvants, and some, mostly mild or
moderate, systemic effects [21,22]. The Global Advisory
Committee on Vaccine Safety GACVS of the World
Health Organisation (WHO) classified these vaccines as
‘extremely safe’, this is seconded by the statements of
many national agencies such as the EMA and Centers
for Disease Control and Prevention (CDC).
Advanced economic modelling from 17 studies across
26 countries reported large between-country disparities,
while the vaccine is highly cost-effective in almost all
countries and particularly low-resource settings [23].
Countries likely to benefit the most because of lack of
organised screening and high disease burden are those
that have yet to introduce nationwide vaccination
programmes.4. Who should be vaccinated?
Current national vaccination programs aim girls, and
in a growing number of countries (Austria, Croatia,
Czech Republic, Denmark, Finland, Germany, Italy,
Norway, Slovakia, Switzerland, and UK in Europe; the
US, Canada, New Zealand and Australia outside
Europe) also boys, before the onset of puberty. A few
more countries have a recommendation but no funding
for boys. The vaccine is licensed from the age of 9 years.
On a population level, HPV vaccination is most effective
when vaccination is administered early in life and should
be given as early as possible in agreement with national
guidelines and programs. This gives the optimal immu-
nologic response and decreases the likelihood of HPV
positivity at the time of vaccination.
Vaccination in older age groups can also offer some
protection against HPV-related disease. The vaccines
have been demonstrated to prevent new infections and
disease up to the age of 45 years [7]. In Australia, it has
been demonstrated that a catch-up program up to the
age of 26 years makes the effects of a vaccination pro-
gram visible earlier than a program just aiming at the
primary target population of prepubertal girls aged
11e13 years. Studies have also shown that this is cost-
effective, although this rapidly declines beyond the age
of 25 years [24]. The use of the vaccine in older women
can also be beneficial at an individual level, but a catch-
up program for older women when compared withHPV-based primary screening does not appear to have
favourable cost-effectiveness profile for population-
based vaccination in developed countries [25].5. Universal HPV vaccination and herd protection
Although cervical cancer is the most important HPV-
related neoplasm globally, other malignancies have been
causally associated with HPV. HPV-related oropha-
ryngeal and anal cancer is on the rise, predominately in
men. For vaccination programs aiming solely at girls,
the protection of men is dependent on the vaccination
status of their female partners, and they leave men who
have sex with men unprotected. For this reason,
Austria, the US, Australia, recently Germany, the UK
and other countries have implemented gender-neutral
vaccination. Vaccination of men not only protects them
directly from HPV-related cancers but also reduces cir-
culation of the virus from unvaccinated cohorts and
therefore expedites benefits to women, through a process
known as herd protection. Furthermore, in countries
with a suboptimal coverage in women that does not
exceed 70%, the impact from vaccination with lower
coverage can be improved by gender-neutral vaccination
immediately, as shown by Lehtinen et al. [26] in a
community-based randomised controlled trial (RCT)
from Finland. In addition, the resilience of a vaccination
program is improved by a gender-neutral approach [27].
An important role of the current prevention campaigns
is to educate and counsel mothers to give the next gen-
eration a better protection, regardless of the sex.
The feasibility of a gender-neutral vaccination pro-
gram depends on the local resources but should be the
preferred concept. The cost-effectiveness of vaccination
of prepubertal boys appears to be dependent on the
coverage of girls in individual countries and settings [28].6. Women with HPV-related disease and prior local
treatment
The vaccines are also effective in sexually active women
and men with previous but cleared infections. The
analysis of data from a subset of 2617 women from 3
clinical studies who were HPV seropositive but DNA
negative found that no subject receiving HPV 6/11/16/18
vaccine developed disease to a type included in the
vaccine to which they were seropositive and DNA
negative at enrolment as opposed to 7 cases of cervical
disease and 8 cases of external genital disease related to
a vaccine HPV type they had previously encountered in
the placebo group [29]. These data suggested that
although the vaccine confers protection from reinfection
or reactivation, natural immunity from induced anti-
bodies does not protect over time.
The efficacy and cost-effectiveness of vaccination
after local conservative treatment for cervical
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the NOVEL trial will start recruitment in 2019. Women
after local treatment remain a high-risk group who are
in need of risk-reducing adjuvant treatments as the
recurrence rate for high-grade preinvasive disease can be
as high as 5e10%, while the risk of invasive cervical
cancer in these women remains two- to four-fold higher
than that in the general population. These women who
develop CIN in the first place constitute a subgroup of
the infected women who are particularly sensitive to the
infection and as a result rapidly acquire reinfections
after treatment. Secondary analyses of the phase III
RCTs and retrospective studies provide indirect evi-
dence that after treatment for HPV-related disease, and
mainly after treatment for cervical HSIL, the onset of
new cervical or other HPV-related disease can be sub-
stantially reduced by HPV vaccination [30e33]. Because
these patients have an increased risk for other HPV-
related disease and cancer [34], vaccination can be
offered on an individual basis.7. Setting
It appears that school-based programs or other well-
organised public health structures are most effective and
ensure equity and hence far superior to opportunistic
vaccination [35]. As school-based vaccination may not
be feasible in every country, the decision on the setting
that could optimise coverage should be in line with the
local infrastructure and resources. Funding is crucial to
implement nationwide vaccination.8. Dosage
Early vaccination provides a superior immune response,
and it has been shown that 2 doses in 9- to 13-year-old
children elicited even higher antibody levels than 3 doses
in young adults [36]. The WHO recommends this prac-
tice for those younger than 15 years. It is important that
the interval between the 2 doses must be 6e12 months.
If the second dose is given within 4 months or less from
the first dose, there is no difference in the antibody
response to that of a single dose. One-dose regimes are
under investigation but cannot be recommended at
present.
Long-term follow-up data from the randomised trials
report high antibody titres and clinical efficacy 12 years
after vaccination [37]. To date, there is no evidence to
support the need for a booster, although protection may
be lifelong.
The protection against HPV 16/18erelated disease is
crucial as these two subtypes cause the highest burden of
the disease. For those already vaccinated with a first-
generation HPV vaccine, routine ‘revaccination’ with
the ninevalent HPV vaccine is possible. To achieve the
full protection against the five (or seven) new HPVtypes, a full course of 3 doses (2 doses for those younger
than 15 years) has to be applied [38]. Although such a
practice on an individual basis is possible, the balance of
cost and effectiveness does not permit recommendation
of vaccination in population-based programs.9. HPV-FASTER: combined strategies of HPV
vaccination and HPV screening
HPV screening and vaccination are complementary
preventive options often implemented as separate and
non-coordinated programs. The HPV-FASTER proto-
col aims to address this disconnect by combining both
strategies with the ultimate purpose of accelerating the
reduction of cervical cancer incidence and mortality [39].
Vaccination can offer protection to women without a
current infection or disease, irrespective of previous viral
exposure, and among those currently infected, vaccina-
tion can protect against further infections and reinfection
with the same HPV type. Importantly, no safety concerns
were reported for women who were HPV positive and
received three doses of HPV vaccine. In accordance with
these findings, the proposal of the HPV-FASTER pro-
tocol is to offer HPV vaccination to women in a broad
age range of 9e45 years, irrespective of HPV infection
status. Women older than 25/30 years would, in addition
to the vaccination, be screened using a validatedHPV test
as part of their initial visit. Indeed, with adequate follow-
up of women who test positive for HPV at presentation
for vaccination, subsequent lifetime risk of cervical can-
cer should be very low, tending to zero. A major benefit
from the HPV-FASTER protocols is that the predicted
subsequent needs for screening may be dramatically
reduced to one/two per lifetime, thus increasing sustain-
ability and compliance as well as alleviation of the burden
and workload at the health centres, typically overloaded
already with patient care.10. Conclusion
With the introduction of HPV vaccination and the
increased accuracy of HPV testing in primary screening,
there is the potential to almost eliminate cervical cancer.
Furthermore, the vaccines can further substantially
reduce the burden of preinvasive disease and other
HPV-related cancers, such as anal, oropharyngeal,
vulvar and vaginal cancer, with further benefits. In
contrast to the cervix, no screening is available for these
sites. The infrastructure required for national vaccina-
tion is far more easily implemented than national call
and recall screening programs, with high coverage
making prevention more accessible in low-income set-
tings. The available vaccines have excellent safety pro-
files, while population-based data from vaccinated
cohorts in the real world outside clinical trials have
proven that the vaccines are highly effective in the real
E.A. Joura et al. / European Journal of Cancer 116 (2019) 21e26 25world, especially in those countries with a good
coverage.
The European Society of Gynecologic Oncology
(ESGO) supports vaccination programs for children and
young adolescents, with a catch-up program for young
adults, if feasible, and also vaccination on an individual
basis. Gender-neutral vaccination improves the protec-
tion of women and men, while it maximises benefits
from vaccination at lower coverage. Individuals with a
history of infection or previous treatment of HPV-
related disease may also get a benefit from vaccina-
tion. The ESGO and the European Federation for
Colposcopy are committed to provide appropriate in-
formation and education for women, not only in their
role as patients but also even more importantly in their
role as mothers of the next generation.
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